These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 27465929)

  • 21. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
    Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
    Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
    Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
    Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in
    Zhao M; Gu W; Liu F; Yu L; Shu Y; Liu L; Hu J; Liu Y; Tang H; Mao J
    Pediatr Dev Pathol; 2023; 26(2):124-132. PubMed ID: 36775958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).
    Lorenzana AN; Zielenska M; Thorner P; Gerrie B; Weitzman S; Squire J
    Pediatr Pathol Lab Med; 1997; 17(6):875-83. PubMed ID: 9353827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients.
    Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A
    Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
    Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
    J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting amplification of
    Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
    Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor.
    Kato K; Nagai JI; Goto H; Shinkai M; Kitagawa N; Toyoda Y; Nishi T; Kigasawa H; Tanaka M; Kurosawa K; Ito Y; Haruta M; Kamijo T; Yoshimi A; Tsuchida M; Nagahara N; Tanaka Y
    Hum Cell; 2024 Sep; 37(5):1602-1609. PubMed ID: 39080217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma-research by one institute.
    Winnicka D; Skowera P; Stelmach M; Styka B; Lejman M
    Acta Biochim Pol; 2024; 71():12821. PubMed ID: 39049899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
    Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
    Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYCN gene amplification in patients with neuroblastic tumors.
    Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
    Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.